kaiser semaglutide criteria 📌 Starting January 1, 2025, Permanente will be making adjustments to the coverage of GLP-1 drugs and other Anti-Obesity Medications (AOMs) in California commercial plans., For members with a Ozempic for Weight Loss: BMI

doi: 10.2471/BLT.06.033647 Alatorre C, Fernndez Land L, Yu M, et al

The nausea, vomiting, and diarrhea commonly associated with semaglutide therapy can lead to reduced fluid intake or increased fluid loss, potentially resulting in dry mouth (xerostomia)

Prolonged use of stimulant laxatives can lead to dependence and electrolyte imbalances

However, the prior observation period in the cohort design and exclusion of the first year of observation in the self-controlled case series analysis increased the likelihood that the cases represented incident NAION

Martinez, R., et al

While primarily prescribed for diabetes management, weight management may be a side-impact of Ozempic